{"classes":[{"categories":[{"measurements":[{"comment":"95% confidence interval could not be calculated due to an insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"100"},{"comment":"95% confidence interval could not be calculated due to an insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100"},{"comment":"95% confidence interval could not be calculated due to an insufficient number of participants with events","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"100"}]}],"title":"3 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93.0","upperLimit":"99.9","value":"99"},{"comment":"95% confidence interval could not be calculated due to an insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100"},{"groupId":"OG002","lowerLimit":"95.3","upperLimit":"99.9","value":"99.3"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.2","upperLimit":"99.5","value":"98"},{"comment":"95% confidence interval could not be calculated due to an insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100"},{"groupId":"OG002","lowerLimit":"94.7","upperLimit":"99.7","value":"98.6"}]}],"title":"9 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.2","upperLimit":"99.5","value":"98"},{"groupId":"OG001","lowerLimit":"85.8","upperLimit":"99.7","value":"97.9"},{"groupId":"OG002","lowerLimit":"93.8","upperLimit":"99.3","value":"98"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.1","upperLimit":"97.8","value":"94.9"},{"groupId":"OG001","lowerLimit":"81.2","upperLimit":"97.9","value":"93.5"},{"groupId":"OG002","lowerLimit":"89.2","upperLimit":"97.2","value":"94.5"}]}],"title":"24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.3","upperLimit":"89.8","value":"83.6"},{"groupId":"OG001","lowerLimit":"75.4","upperLimit":"95.3","value":"88.9"},{"groupId":"OG002","lowerLimit":"78.3","upperLimit":"90.3","value":"85.4"}]}],"title":"48 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.6","upperLimit":"84.5","value":"76.3"},{"groupId":"OG001","lowerLimit":"70.9","upperLimit":"93.5","value":"85.9"},{"groupId":"OG002","lowerLimit":"71.0","upperLimit":"86.0","value":"79.7"}]}],"title":"60 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"151"}],"units":"Participants"}],"description":"Overall survival rate was defined as the time from the first dose to death due to any cause. Patients who were still alive were censored at the last date the patient was known to be alive. Overall survival rate is a Kaplan-Meier estimate of the survivor function at each specific time point. The 95% CI is calculated using the Greenwood's formula with a log-log transformation. Percentage is calculated using the number of patients in the column heading as the denominator.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Carcinoma in situ (CIS) with or without concomitant high-grade Ta or T1 papillary disease","id":"OG000","title":"Carcinoma in Situ"},{"description":"Patients with high-grade Ta or T1 papillary disease (without concomitant CIS)","id":"OG001","title":"Papillary Disease"},{"description":"All patients","id":"OG002","title":"Total"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"60 Months","title":"Overall Survival Rate in All Patients","type":"SECONDARY","unitOfMeasure":"percentage of patients"}